Description
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Sacramento: Please contact Isabel Rodrigues-Fong Rodrigi@sutterhealth.org and Kirsten Babski babskik@sutterhealth.org
Modesto: Please contact Delia Massone MassonD@sutterhealth.org and Adrienne Palos PalosA@sutterhealth.org
Solano-Vallejo Cancer Center: Please contact Stephanie Gonzales gonzals@sutterhealth.org
View study details on ClinicalTrials.gov
Principal Investigator
Co-Investigator(s)
Saunders C. Hsu, M.D, YiSheng Lee, M.D.
Recruitment Status
Active, Not Recruiting
Start Date
February 01, 2019